GLP-1 weight-loss drugs linked to slower cancer progression

Overview

A study of more than 12,000 patients found that those taking GLP-1 weight-loss drugs were 38% to 50% less likely to progress to stage IV cancer in four obesity-linked cancers. Cleveland Clinic researchers matched GLP-1 users — on drugs like Ozempic, Wegovy, and Mounjaro — against patients taking older diabetes pills.

The data is observational, not from a randomized trial, but the effect sizes drew wide attention after the ASCO announcement. A separate Roswell Park study due June 1 found GLP-1 drugs cut chemotherapy response rates in triple-negative breast cancer from 65% to 31%, a direct counterpoint.

Why it matters

Drugs already in millions of medicine cabinets may quietly cut the deadliest stage of cancer in half — if randomized trials confirm it.

Play on this story Voices Debate Predict Higher or Lower

Key Indicators

12,112

Patients in matched cohort

Half started a GLP-1 after a stage I-III cancer diagnosis; half took an older diabetes drug.

50%

Lower stage IV risk in lung cancer

Non-small cell lung cancer patients on GLP-1s saw progression cut in half (HR 0.50).

43%

Lower stage IV risk in breast cancer

Breast adenocarcinoma progression dropped from 20.1% to 10.2% over the study window.

Cancer types studied

Breast, prostate, lung, colorectal, liver, kidney, and pancreatic adenocarcinomas.

33%

Lower death risk with high tumor GLP-1 receptor

Tumors expressing more GLP-1 receptors were linked to better survival, suggesting a direct mechanism.

Voices

Curated perspectives — historical figures and your fellow readers.

Ever wondered what historical figures would say about today's headlines?

Play

Exploring all sides of a story is often best achieved with Play.

Predict 5 ways this could play out. Contrarian picks score more — points lock when the scenario resolves. Log in to play

Higher or Lower Two numbers from this story. Guess which is bigger. 5 rounds to set a streak. Log in to play

Connections Sixteen names from the news. Find the four hidden groups of four. Log in to play

People Involved

Mark David Orland

Lead author presenting the study at ASCO 2026

Sheheryar Kabraji

Senior author on a GLP-1 and triple-negative breast cancer study being presented at ASCO 2026 on June 1

Organizations Involved

Taussig Cancer Institute, Cleveland Clinic

Academic medical center

Home institution of the lead investigator

Cleveland Clinic's cancer arm, one of the largest US oncology programs by patient volume.

American Society of Clinical Oncology

Professional medical society

Host of the meeting where the findings debuted

The world's largest oncology society, whose annual meeting sets the agenda for cancer research.

Novo Nordisk

Pharmaceutical company

Maker of semaglutide (Ozempic, Wegovy), one of the drugs studied

Danish drugmaker that pioneered the GLP-1 category and remains its dominant supplier.

Eli Lilly and Company

Pharmaceutical company

Maker of tirzepatide (Mounjaro, Zepbound), included in the GLP-1 cohort

US drugmaker whose tirzepatide combines GLP-1 with a second gut hormone receptor.

Roswell Park Comprehensive Cancer Center

Academic medical center

Presenting GLP-1 and breast cancer data at ASCO 2026 on June 1 that challenges the Cleveland Clinic's positive findings

Major US cancer center in Buffalo, New York, with research entering the ASCO 2026 GLP-1 debate on the side of caution.

Timeline

2005 June 2026

9 events Latest: June 1st, 2026

Tap a bar to jump to that date

June 2026
Roswell Park presents GLP-1 and aggressive breast cancer data at ASCO
Latest Research

Roswell Park researchers, with Sheheryar Kabraji as senior author, present findings on GLP-1 receptor agonists in aggressive breast cancer at ASCO in Chicago — a study that finds the drugs may cut chemotherapy response rates in triple-negative breast cancer roughly in half.
June 1st, 2026 • 1:30 PM
May 2026
Findings presented at ASCO 2026 in Chicago
Research

Orland reports that GLP-1 users with stage I-III cancer were 38%-50% less likely to progress to stage IV in lung, breast, colorectal, and liver cancers.
In 5 days
ASCO releases Cleveland Clinic abstract early
Research

The press embargo lifts on Orland's metastatic progression data ahead of the formal meeting.
3 days ago
August 2025
JAMA Oncology study extends signal to obesity patients
Research

OneFlorida+ data shows GLP-1 users with obesity had a 17% lower cancer risk than non-users.
August 15th, 2025
July 2024
JAMA study links GLP-1s to lower cancer risk in diabetes
Research

Case Western analysis of diabetic patients finds GLP-1 users have lower incidence of 10 of 13 obesity-related cancers.
July 5th, 2024
May 2022
Mounjaro approved for diabetes
Regulatory

Eli Lilly's tirzepatide enters the market with weight-loss numbers larger than semaglutide's.
May 13th, 2022
June 2021
FDA approves Wegovy for obesity
Regulatory

Higher-dose semaglutide is cleared for chronic weight management, the first new obesity drug class in years.
June 4th, 2021
2017
Ozempic launches in the US
Product launch

Novo Nordisk's weekly semaglutide injection arrives for diabetes and quickly draws off-label weight-loss demand.
2017
2005
First GLP-1 drug approved
Regulatory

FDA clears exenatide (Byetta) for type 2 diabetes, opening the GLP-1 receptor agonist class.
2005

Historical Context

3 moments from history that rhyme with this story — and how they unfolded.

1988

Aspirin and colorectal cancer (1988)

A Melbourne case-control study by Kune and colleagues found regular aspirin users had about 40% lower colorectal cancer risk. The signal came from a drug already taken by millions for pain and heart disease.

Then

Larger cohort studies in the 1990s confirmed the association. Researchers began running randomized trials with cancer endpoints.

Now

By 2016 the US Preventive Services Task Force recommended low-dose aspirin for some adults to prevent colorectal cancer, though the guidance was scaled back in 2022 over bleeding risk.

Why this matters now

Aspirin is the closest analog: a widely used drug that turned out to have a cancer-prevention signal, took two decades to confirm, and never fully escaped controversy. GLP-1s may follow the same arc.

2005

Metformin's cancer signal (2005)

A Scottish observational study found diabetics taking metformin had lower cancer incidence than those on other diabetes drugs. The finding launched hundreds of follow-up studies.

Then

Metformin became one of the most-studied repurposing candidates in oncology, with trials in breast, prostate, and pancreatic cancer.

Now

Most randomized trials, including the large MA.32 breast cancer trial reported in 2022, failed to show survival benefit. The observational signal did not hold up under randomization.

Why this matters now

Metformin is the cautionary tale: an observational comparison against other diabetes drugs that did not survive randomized testing. GLP-1 researchers will be asked why their data is different.

October 2020

HPV vaccine and cervical cancer (2020)

A Swedish registry study of 1.67 million women, published in the New England Journal of Medicine, showed the HPV vaccine cut invasive cervical cancer by 88% in women vaccinated before age 17.

Then

The data ended a decade of debate about whether antibody studies would translate to actual cancer reduction.

Now

Several countries accelerated school-based vaccination programs and expanded coverage to boys.

Why this matters now

A reminder that large registry studies can produce cancer-prevention numbers strong enough to change practice without waiting for randomized trials, if the effect size is big and the data are clean.